Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
RVL Pharmaceuticals plc (OSMT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
09/29/2023 8-K Other Events  Interactive Data
08/25/2023 8-K Regulation FD Disclosure  Interactive Data
08/18/2023 8-K Quarterly results
08/14/2023 8-K Quarterly results
Docs: "RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review"
08/02/2023 8-K Resignation/termination of a director
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/02/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/11/2023 8-K Quarterly results
Docs: "RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update"
03/20/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
01/09/2023 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/18/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ Net Product Sales"
08/11/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/11/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/06/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ Net Product Sales Results"
04/04/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FIRST Amendment to License Agreement"
03/30/2022 8-K Quarterly results
Docs: "RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Preliminary First Quarter 2022 UPNEEQ® Revenue Estimate and Business Update"
01/19/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance -- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical aesthetics expected to commence in February 2022 -- -- Company to host video webcast at 8:30am ET on January 19, 2022 --"
01/18/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF RVL PHARMACEUTICALS PUBLIC LIMITED COMPANY COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF RVL PHARMACEUTICALS PUBLIC LIMITED COMPANY 1. The name of the Company is RVL Pharmaceuticals public limited company. 2. The Company is a public limited company for the purposes of Part 17 of the Companies Act 2014. 3. The objects for which the Company is established are: 3.1. To carry on the business of a holding company and to coordinate the administration, finances and activities of any subsidiary companies or associated companies, to do all lawful acts and things whatsoever that are necessary or convenient in carrying on the business of such a holding company and in particular to carry on, in all its branches, th..."
11/17/2021 8-K Regulation FD Disclosure  Interactive Data
11/15/2021 8-K Quarterly results
Docs: "Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update"
11/10/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "[Remainder of page intentionally left blank.]"
10/12/2021 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister...
Docs: "UNDERWRITING AGREEMENT",
"ORDINARY SHARE PURCHASE WARRANT OSMOTICA PHARMACEUTICALS PLC Warrant Shares: Initial Exercise Date: October 12, 2021 THIS ORDINARY SHARE PURCHASE WARRANT certifies that, for value received, _______ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on April 14, 2025 but not thereafter, to subscribe for and purchase from Osmotica Pharmaceuticals plc, an Irish incorporated public limited company , up to ______ Ordinary Shares , provided that, if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the Warrant Shares to the Holder at any time during the term of this Warra...",
"A&L Goodbody International Financial Services Centre 25-28 North Wall Quay, Dublin 1 D01 H104 T: +353 1 649 2000 DX: 29 Dublin | www.algoodbody.com Dublin Belfast London New York San Francisco Palo Alto Date 12 October 2021 Our ref 01427724 Your ref Osmotica Pharmaceuticals plc 25-28 North Wall Quay Dublin 1 Ireland Re: Osmotica Pharmaceuticals plc",
"PART II"
10/06/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Note Purchase Agreement dated October 1, 2021, between Osmotica Pharmaceutical Corp., Osmotica Pharmaceuticals plc, Osmotica Holdings US LLC, Athyrium Opportunities IV Acquisition LP and the Purchasers from time to time party thereto",
"Share Subscription Agreement dated October 1, 2021, between Osmotica Pharmaceuticals plc and Athyrium Opportunities IV Acquisition LP"
09/27/2021 8-K Quarterly results
09/08/2021 8-K Quarterly results
09/08/2021 8-K Quarterly results
09/02/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy